Clinical and pharmacological group: & nbsp

Antibiotics

Antiseptics and disinfectants

Other synthetic antibacterial agents

Included in the formulation
  • Gairo
    pills inwards 
  • Dazolik
    pills inwards 
  • Quinizole
    solution d / infusion 
    ARS, LLC     Russia
  • Quinizole
    pills inwards 
  • Ornidazole
    pills inwards 
    VERTEKS, AO     Russia
  • Ornidazole
    pills
    VERTEKS, AO     Russia
  • Ornidazole
    pills inwards 
  • Ornidazole
    pills inwards 
    ATOLL, LLC     Russia
  • Ornidazole-Vero
    pills inwards 
    VEROPHARM SA     Russia
  • Ornidazole-OBL
    pills inwards 
  • Ornidozole-OBL
    pills inwards 
  • Ornisid
    pills inwards 
  • Ornisid
    pills the vagina. 
  • Orniside Forte
    pills inwards 
  • Tiberal®
    pills inwards 
  • АТХ:

    G.01.A.F.06   Ornidazole

    Pharmacodynamics:

    The derivative of 5-nitroimidazole, breaks the structure of DNA-sensitive microorganisms. The drug is active against Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica, as well as some anaerobic bacteria (Bacteroides spp., Clostridium spp., Fusobacterium, anaerobic cocci).

    Pharmacokinetics:

    Rapidly absorbed from the gastrointestinal tract, bioavailability - 90%, maximum concentration in the blood is reached within 3 hours after administration, binds to plasma proteins by 15%. Penetrates through the blood-brain barrier, the half-life is 13 hours. Excreted by the kidneys (60-70%) and the gastrointestinal tract (20-25%), of which 5% unchanged.

    Indications:

    Trichomoniasis (urinary tract infections caused by Trichomonas vaginalis).

    Amoebiasis (intestinal infections caused by Entamoeba histolytica, including amoebic dysentery, extraintestinal amoebiasis, including amoebic liver abscess).

    Giardiasis.

    Prevention of infections caused by anaerobic bacteria, in operations on the colon and in gynecology; for vaginal tablets - urogenital trichomoniasis; nonspecific vaginitis of different etiology, confirmed by clinical and microbiological data.

    I.A00-A09.A06   Amebiasis

    I.A00-A09.A06.0   Acute amoebic dysentery

    I.A00-A09.A06.4   Amoebic liver abscess

    I.A00-A09.A06.9   Amebiasis, unspecified

    I.A00-A09.A07.1   Giardiosis (giardiasis)

    I.A50-A64.A59   Trichomoniasis

    I.A50-A64.A59.0   Urogenital trichomoniasis

    XIV.N70-N77.N76.8   Other specified inflammatory diseases of the vagina and vulva

    XXI.Z20-Z29.Z29.8   Other specified preventive measures

    Contraindications:

    Diseases of the central nervous system.

    I trimester of pregnancy.

    Hypersensitivity.

    Organic diseases of the central nervous system (including epilepsy and multiple sclerosis).

    Lactation period.

    Pathological changes in blood and blood cell abnormalities.

    Children under 3 years old, and body weight less than 20 kg.

    Carefully:

    Diseases of the liver.

    Alcoholism.

    Pregnancy II and III trimester.

    Children over 3 years old and weighing more than 20 kg.

    To patients of advanced age.

    Pregnancy and lactation:

    Category FDA not determined. Do not take if breastfeeding and in I trimester of pregnancy.

    Dosing and Administration:

    Orally: adults - 0.5-2 g (depending on body weight); children weighing up to 35 kg - 20-40 mg / kg. Duration of treatment and the frequency of reception is determined individually by the doctor.

    Intravenous: adults - 0.5-1 g; children 20-30 mg / kg per day. The duration of treatment is set individually by the doctor.

    Intravaginally, deeply, after hygienic treatment of the external genitalia, 1-2 g /day.

    Trichomoniasis: 0.5 g 2 times a day (morning and evening) for 5 days; also simultaneously appoint one vaginal tablet (500 mg) overnight (after hygienic treatment of the vulva, the vaginal tablet should be injected deep into the vagina). In women: inside 1-2 g once; in combination with intravaginal application - 0.5 g once; effectiveness increases with the treatment of both sexual partners.

    Intestinal amebiasis: adults and children weighing more than 35 kg - 1.5 g once a day, more than 60 kg - 2 g per day for 3 days.

    Chronic amoebiasis: 10 mg / kg / day for 10 days.

    Extraintestinal amebiasis, including amoebic liver abscess: adults and children over 12 years - 0.5 g orally 2 times a day 5-10 days or 1 g 2 times a day 1 day.

    Giardiasis: adults and children weighing more than 35 kg - inside 1.5 g once a day for 1-2 days, the dose can be increased to 2 g; The single dose of tinidazole is most rational.

    Prevention of anaerobic infections in operations on the colon: 1 g before the operation, then 0.5 g 2 times a day for 2-5 days (in combination with ceftriaxone) and in gynecology.

    Side effects:

    On the part of the nervous system: headache, impaired consciousness, drowsiness, fatigue, dizziness, tremor, impaired coordination, rigidity of the muscles, sensory or mixed peripheral neuropathy, seizures.

    From the gastrointestinal tract: heartburn, nausea, vomiting, perversion of taste sensations (metallic taste in the mouth), diarrhea, change in the activity of liver enzymes.

    From the immune system: hypersensitivity reactions, skin rash, itching, urticaria, and Quincke's edema.

    Overdose:

    Depression, epileptiform cramps, peripheral neuritis. Treatment is symptomatic, with convulsions - diazepam.

    Interaction:

    Simultaneous reception of anticoagulants coumarinovogo number can lead to increased bleeding.

    The drug is compatible with ethanol.

    Vecuronium bromide is the prolongation of myorelaxing action.

    When co-administered with phenobarbital or other inducers of hepatic liver enzymes (for example, cimetidine) there is an increase in the concentration of ornidazole.

    Special instructions:

    In the treatment of trichomoniasis, simultaneous treatment of both partners should be carried out.

    In the course of treatment, there may be worsening of the course of diseases of the peripheral nervous system. When symptoms of peripheral neuropathy, ataxia, dizziness or confusion arise, treatment should be suspended.

    In patients on hemodialysis, a reduced half-life is observed. You may need to adjust the dose of the drug.

    Impact on the ability to drive vehicles and manage mechanisms

    During the period of treatment, it is not recommended to drive vehicles and engage in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

    Instructions
    Up